Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 384

1.

Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.

Tsang JY, Ni YB, Chan SK, Shao MM, Law BK, Tan PH, Tse GM.

Ann Surg Oncol. 2014 Jul;21(7):2218-28. doi: 10.1245/s10434-014-3629-2. Epub 2014 Mar 18.

PMID:
24639191
2.

Immunohistochemically defined subtypes and outcome of apocrine breast cancer.

Dellapasqua S, Maisonneuve P, Viale G, Pruneri G, Mazzarol G, Ghisini R, Mazza M, Iorfida M, Rotmensz N, Veronesi P, Luini A, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2013 Apr;13(2):95-102. doi: 10.1016/j.clbc.2012.11.004. Epub 2012 Dec 14.

PMID:
23245877
4.

Differential impact of the expression of the androgen receptor by age in estrogen receptor-positive breast cancer.

Tokunaga E, Hisamatsu Y, Taketani K, Yamashita N, Akiyoshi S, Okada S, Tanaka K, Saeki H, Oki E, Aishima S, Oda Y, Morita M, Maehara Y.

Cancer Med. 2013 Dec;2(6):763-73. doi: 10.1002/cam4.138. Epub 2013 Sep 30.

5.

Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.

Choi JE, Kang SH, Lee SJ, Bae YK.

Ann Surg Oncol. 2015 Jan;22(1):82-9. doi: 10.1245/s10434-014-3984-z. Epub 2014 Aug 22.

PMID:
25145503
6.

Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.

Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F.

Hum Pathol. 2008 Feb;39(2):167-74. Epub 2007 Nov 28.

PMID:
18045647
7.

Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.

Nassar A, Sussman ZM, Lawson D, Cohen C.

Breast J. 2012 Sep;18(5):399-405. doi: 10.1111/j.1524-4741.2012.01279.x. Epub 2012 Aug 10.

PMID:
22882580
8.

RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.

Habashy HO, Powe DG, Glaab E, Ball G, Spiteri I, Krasnogor N, Garibaldi JM, Rakha EA, Green AR, Caldas C, Ellis IO.

Breast Cancer Res Treat. 2011 Jul;128(2):315-26. doi: 10.1007/s10549-010-1073-y. Epub 2010 Aug 10.

PMID:
20697807
9.

Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.

Kuzhan A, Adli M, Eryigit Alkis H, Caglayan D.

J BUON. 2013 Jul-Sep;18(3):619-22.

PMID:
24065473
10.

Expression of AIB1 protein as a prognostic factor in breast cancer.

Lee K, Lee A, Song BJ, Kang CS.

World J Surg Oncol. 2011 Oct 29;9:139. doi: 10.1186/1477-7819-9-139.

11.

Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer?

Arslan C, Isik M, Guler G, Kulac I, Solak M, Turker B, Ozisik Y, Altundag K.

Am Surg. 2012 Sep;78(9):992-9.

PMID:
22964210
12.

Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.

Hisamatsu Y, Tokunaga E, Yamashita N, Akiyoshi S, Okada S, Nakashima Y, Aishima S, Morita M, Kakeji Y, Maehara Y.

Ann Surg Oncol. 2012 Apr;19(4):1145-52. doi: 10.1245/s10434-011-2094-4. Epub 2011 Oct 8.

PMID:
21984487
13.

FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.

Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.

14.

Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers.

Tsang JY, Hui SW, Ni YB, Chan SK, Yamaguchi R, Kwong A, Law BK, Tse GM.

Breast Cancer Res Treat. 2014 Jan;143(1):1-9. doi: 10.1007/s10549-013-2781-x. Epub 2013 Nov 24.

PMID:
24272079
15.

Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.

Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil WH, Kim SW, Lee JE, Nam SJ.

BMC Cancer. 2015 Mar 18;15:138. doi: 10.1186/s12885-015-1121-4.

16.

Expression of androgen receptors in primary breast cancer.

Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW, Lee KS.

Ann Oncol. 2010 Mar;21(3):488-92. doi: 10.1093/annonc/mdp510. Epub 2009 Nov 3.

PMID:
19887463
17.

Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.

Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, Kim SI, Park BW, Lee KS.

Ann Oncol. 2011 Aug;22(8):1755-62. doi: 10.1093/annonc/mdq678. Epub 2011 Feb 10.

PMID:
21310761
18.

The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.

Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P.

Clin Breast Cancer. 2013 Apr;13(2):146-52. doi: 10.1016/j.clbc.2012.11.006. Epub 2013 Jan 11.

PMID:
23318089
19.

Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.

Lin Fde M, Pincerato KM, Bacchi CE, Baracat EC, Carvalho FM.

J Clin Pathol. 2012 Jan;65(1):64-8. doi: 10.1136/jclinpath-2011-200318. Epub 2011 Oct 29.

PMID:
22039288
20.

Fibrotic focus in breast carcinomas: relationship with prognostic parameters and biomarkers.

Mujtaba SS, Ni YB, Tsang JY, Chan SK, Yamaguchi R, Tanaka M, Tan PH, Tse GM.

Ann Surg Oncol. 2013 Sep;20(9):2842-9. doi: 10.1245/s10434-013-2955-0. Epub 2013 Mar 29.

PMID:
23539156

Supplemental Content

Support Center